Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common st...
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestone...
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding...
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing po...
Are you looking for the best penny stocks to buy? You're not alone; many traders are showing a renewed interest in this exciting market....
Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....
JHX, CWCO, GPI, CEG and PIRS have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2023....
If you're looking for penny stocks to buy this week, you've got your work cut out for yourself. Plenty of headwinds will be faced, including more tech earnings and Friday's speech from Fed Chair Jerom...
